BioSpace News Archive

MHA Study Reveals Member Medication Adherence Rates for Long-Term Care Pharmacies Serving Skilled Nursing and Assisted Living Patients

Integrated fintech platform designed to transform existing payment processing ecosystems and improve both aesthetic practice economics and patient experiences - - Provides access to a $500+ million market opportunity in U.S. aesthetic practice payment services - NEWARK, Calif.--( BUSINESS WIRE )-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its invest

Angel Medical Systems INC is pleased to announce the appointment of Gordie Nye as its new Chief Executive Officer

Advanced Urology proudly announces the opening of new satellite offices in Buckhead, Canton, Braselton, and Cumming to provide more patients with the opportunity to receive the best possible urological care from top-notch, board-certified physicians.

UK digital health and therapeutics company Huma is teaming up with the renowned Fenland Study research team at the Medical Research Council (MRC) Epidemiology Unit, University of Cambridge to begin a study to understand the progression and early signs of COVID-19 infection.

Allovate Therapeutics, a New York-based biotechnology company, announced today that it has extended its free Allerdent® program.

Geisinger researchers have concluded there is sufficient evidence to consider including DNA changes that cause neurodevelopmental and psychiatric disorders in genomic screening programs.

Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its second quarter 2020 financial results after the financial markets close on Thursday August 6, 2020.

Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2020 second quarter on Thursday, August 6, 2020 before the open of the U.S. financial markets.

Organogenesis Holdings Inc. announced that the latest advanced wound care research on its Apligraf®, Affinity®, Dermagraft®, Nushield® and PuraPly® AM product lines will be showcased at the 2020 Symposium on Advanced Wound Care Spring | Wound Healing Society Virtual Experience, held July 24-26.